See more : The Ehime Bank, Ltd. (8541.T) Income Statement Analysis – Financial Results
Complete financial analysis of Scilex Holding Company (SCLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scilex Holding Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Jin Medical International Ltd. (ZJYL) Income Statement Analysis – Financial Results
- Diego Pellicer Worldwide, Inc. (DPWW) Income Statement Analysis – Financial Results
- PT Petrosea Tbk (PTRO.JK) Income Statement Analysis – Financial Results
- Medibank Private Limited (MPL.AX) Income Statement Analysis – Financial Results
- Niutech Environment Technology Corporation (688309.SS) Income Statement Analysis – Financial Results
Scilex Holding Company (SCLX)
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
| Cost of Revenue | 15.68M | 10.80M | 3.63M | 2.15M | 5.80M |
| Gross Profit | 31.06M | 27.24M | 27.68M | 21.41M | 15.23M |
| Gross Profit Ratio | 66.45% | 71.61% | 88.40% | 90.88% | 72.41% |
| Research & Development | 12.75M | 9.05M | 9.20M | 9.96M | 85.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 119.64M | 64.90M | 50.58M | 42.97M | 64.70M |
| Other Expenses | 4.11M | 3.92M | 3.74M | 3.74M | 3.71M |
| Operating Expenses | 136.49M | 77.87M | 63.52M | 56.67M | 153.93M |
| Cost & Expenses | 152.17M | 88.67M | 67.16M | 58.82M | 159.73M |
| Interest Income | 0.00 | 9.60M | 11.76M | 13.12M | 460.00K |
| Interest Expense | 1.07M | 9.60M | 39.76M | 13.12M | 16.89M |
| Depreciation & Amortization | 4.15M | 4.45M | 4.15M | 3.78M | 3.75M |
| EBITDA | -109.10M | -9.30M | -44.88M | -31.48M | -134.49M |
| EBITDA Ratio | -233.41% | -122.71% | -102.37% | -133.62% | -639.40% |
| Operating Income | -105.43M | -50.63M | -35.84M | -35.26M | -138.70M |
| Operating Income Ratio | -225.55% | -133.13% | -114.44% | -149.65% | -659.42% |
| Total Other Income/Expenses | -8.89M | 27.27M | -52.58M | -12.31M | -39.90M |
| Income Before Tax | -114.32M | -23.36M | -88.42M | -47.57M | -178.59M |
| Income Before Tax Ratio | -244.57% | -61.42% | -282.34% | -201.92% | -849.10% |
| Income Tax Expense | 13.00K | 4.00K | 5.00K | -53.00K | 2.00K |
| Net Income | -114.33M | -23.36M | -88.42M | -47.52M | -178.59M |
| Net Income Ratio | -244.59% | -61.43% | -282.35% | -201.69% | -849.11% |
| EPS | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| EPS Diluted | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| Weighted Avg Shares Out | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
| Weighted Avg Shares Out (Dil) | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information
PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan
PALO ALTO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024
PALO ALTO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy
PALO ALTO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®
PALO ALTO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch
PALO ALTO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch
PALO ALTO, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)
PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Source: https://incomestatements.info
Category: Stock Reports